KITE-363 CAR-T Trial at Australian Sites for Refractory Lupus
Key Questions
What is the KITE-363 CAR-T trial and where is it being conducted in Australia?
The KITE-363 trial (NCT07038447) is a Phase 1 study recruiting patients with refractory SLE or lupus nephritis at Concord Hospital in Sydney and St Vincent's Hospital in Melbourne. It focuses on CAR-T therapy for patients unresponsive to standard treatments.
What evidence supports the safety of BCMA-CD19 CAR-T therapies in lupus?
Global data on BCMA-CD19 CAR-T therapies show reduced autoantibodies and support their use in refractory cases. This underpins the Australian trial sites and broader immune-reset approaches.
What new findings from EULAR 2026 relate to CAR-T therapies in SLE?
EULAR 2026 data indicate that zorpocabtagene autoleucel reshapes gut microbiota, while CD19/BCMA CAR-T improves skin and lung fibrosis in SLE patients. A review podcast highlights nine Phase 3 programs advancing disease modification.
What progress has Imviva's allogeneic CAR-T made for autoimmune diseases?
Imviva's CTA313 allogeneic CAR-T received FDA IND approval and achieved a 100% SRI-4 response rate in SLE trials. This strengthens the case for off-the-shelf immune-reset options.
How are the Lupus Research Alliance and Genentech supporting CAR-T research?
They are funding three CAR-T projects to elucidate immune reset mechanisms and durable remission. An ACT Brief from November 2026 reinforces views that these therapies could shift standard of care.
What UK evidence supports CAR-T for lupus remission?
NHS real-world data and patient reports show CAR-T inducing remission in autoimmune patients, including lupus cases described as 'groundbreaking.' This provides precedent for Australian PBS advocacy efforts.
What early results has Autolus Therapeutics' obe-cel shown in severe SLE?
Obe-cel demonstrated early promise in the CARLYSLE trial for severe lupus. These findings add to the growing body of CAR-T data for refractory disease.
How might these developments influence Australian access to CAR-T for lupus?
The combination of local trial sites, global safety data, and UK remission evidence supports advocacy for PBS funding. Nine Phase 3 programs and immune-reset narratives could accelerate standard-of-care changes.
Phase 1 trial (NCT07038447) recruiting refractory SLE/LN at Concord (Sydney) and St Vincent's (Melbourne). Bolstered by global BCMA-CD19 CAR-T safety data showing reduced autoantibodies. New EULAR 2026 data: zorpocabtagene autoleucel reshapes gut microbiota, CD19/BCMA CAR-T improves skin/lung fibrosis in SLE. Imviva's CTA313 allogeneic CAR-T received FDA IND approval with 100% SRI-4 response in SLE, further strengthening immune-reset narrative. LRA and Genentech funding three CAR-T projects to understand immune reset mechanisms, supporting durable remission arguments for PBS advocacy. An ACT Brief (Nov 2026) reinforces LRA CEO's view on immune-reset therapies shifting standard of care. A recent EULAR 2026 review podcast reinforces the global shift towards disease modification and immune-reset therapies, with 9 phase 3 programs, providing additional context for Australian PBS advocacy. New developments: Autolus Therapeutics' obe-cel shows early promise in severe SLE (CARLYSLE trial). UK NHS real-world evidence of CAR-T inducing remission in autoimmune patients strengthens precedent for Australian PBS advocacy. A patient narrative from the UK further illustrates the transformative potential of immune reset.